Antisense therapy for hepatitis C virus infection

J Hepatol. 2014 Jan;60(1):227-8. doi: 10.1016/j.jhep.2013.08.028. Epub 2013 Sep 11.

Authors

Ype P de Jong¹, Ira M Jacobson²

Affiliations

¹ Division of Gastroenterology and Hepatology, Center for the Study of Hepatitis C, Weill Cornell Medical College, New York, NY, USA; Laboratory of Virology and Infectious Disease, Center for the Study of Hepatitis C, The Rockefeller University, New York, NY, USA.
² Division of Gastroenterology and Hepatology, Center for the Study of Hepatitis C, Weill Cornell Medical College, New York, NY, USA. Electronic address: imj2001@med.cornell.edu.

PMID: 24036232
DOI: 10.1016/j.jhep.2013.08.028

No abstract available

Keywords: Antisense; DAA; HCV; miR-122.

Publication types

Comment

MeSH terms

Antiviral Agents / therapeutic use*
Female
Hepacivirus / genetics*
Hepatitis C, Chronic / drug therapy*
Humans
Male
MicroRNAs*
Oligonucleotides / therapeutic use*

Substances

Antiviral Agents
MicroRNAs
Oligonucleotides

Grants and funding

K08 DK090576/DK/NIDDK NIH HHS/United States